Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

GR63178A

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
SummaryGR63178A is a water-soluble analogue of mitoquidone, a pentacyclic pyrroloquinone. This group of drugs exhibit a novel… Expand
  • table 1
  • table 2
2004
2004
The novel anticancer compound GR63178A is being evaluated in the clinic, having demonstrated activity against a wide range of… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • table 1
1993
1993
Abstract— The effect of temperature, pH, light, drug concentration and aeration on the stability of aqueous solutions of GR63178A… Expand
1992
1992
A total of 91 eligible patients with metastatic cancer have been treated in a series of phase II trials of the novel pentacyclic… Expand
1992
1992
In a Phase I study fosquidone was administered to 23 patients (15 female, 8 male; mean age 53.6 years) with various solid tumours… Expand
1992
1992
GR63178A (NSC D611615) is the second pentacyclic pyrolloquinone to be evaluated clinically as an anticancer drug. Its mechanism… Expand
1992
1992
A total of 61 eligible patients with metastatic cancer have been treated in a series of Phase II trials of the novel pentacyclic… Expand
  • table I
  • table II
1990
1990
Compounds of a new group of pentacyclic pyrroloquinones have been shown to have activity against several experimental tumour… Expand
  • figure 1
  • table I
  • table II
  • table III
  • table IV